Xu Yuan — SEC Form 4 filings
SEC reporting owner CIK 1858214. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-15.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-06-11 to 2026-06-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 633 shares, $2,678 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 633 shares @ $4.23 ($2,678) in FATE THERAPEUTICS INC, filed 2024-08-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | Director | 4 | — | 1 leg · 633 sh · $2,678 | 3 |
| Akero Therapeutics, Inc. (AKRO) | Director | 3 | — | — | 8 |
| Xilio Therapeutics, Inc. (XLO) | Director | 3 | — | — | 3 |
Form 4 filings — Xu Yuan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 87,900 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 26,000 (derivative) | EDGAR |
| 2025-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 9,398 @ $0 | EDGAR |
| 2025-05-30 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2024-08-07 | 4 | FATE THERAPEUTICS INC (FATE) | Sale (S): 633 @ $4.23 | EDGAR |
| 2024-06-17 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1858214 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →